Acoramidis, a novel therapeutic agent, has shown promising long-term efficacy in treating transthyretin amyloid cardiomyopathy (ATTR-CM), as evidenced by data from the ongoing open-label extension (OLE) of the ATTRibute-CM trial. This multicenter study reported that continuous treatment with acoramidis resulted in significant reductions in all-cause mortality (ACM) and cardiovascular-related mortality (CVM), with hazard ratios of 0.55 and 0.51, respectively, through month 54. The trial included 632 participants, predominantly elderly, with a mean age of 77.3 years, highlighting the drug’s potential relevance in an aging population.

The findings underscore the clinical significance of acoramidis in stabilizing transthyretin levels and mitigating disease progression in ATTR-CM. Continuous treatment not only reduced mortality risks but also maintained stable biomarkers such as N-terminal pro-B-type natriuretic peptide (NT-proBNP) and improved functional capacity as measured by the 6-minute walk distance (6MWD) and the Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS) score. These results suggest that acoramidis effectively enhances patient outcomes and quality of life, addressing a condition that has often been under-recognized despite its prevalence in older adults.

The implications of this study extend beyond immediate therapeutic benefits; they challenge the current perception of transthyretin amyloidosis as a rare disease. As evidence mounts regarding its widespread impact on cardiovascular health in the elderly, there is an urgent need for the medical community to reconsider treatment accessibility and pricing structures. The long-term efficacy data for acoramidis may catalyze a shift in drug development and regulatory approaches, ultimately leading to broader availability and affordability of treatments for this significant yet underappreciated condition in aging populations.

Source: fightaging.org